SEC Filing Summary: BioSig Technologies, Inc. (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BioSig Technologies, Inc. (not Streamex Corp.) on August 28, 2020. The registrant is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol BSGM. The report details the entry into a material definitive agreement regarding a new equity financing facility.
Key Financial Metrics and Transaction Details
The filing does not report standard operating metrics such as revenue, profit, cash flow, or debt levels for a specific period. Instead, it outlines the following transaction parameters:
- Agreement Type: Open Market Sale Agreement (At-the-Market Offering).
- Counterparty: Jefferies LLC (acting as sales agent and/or principal).
- Maximum Offering Size: Up to $45,000,000 of common stock.
- Commission: 3.0% of gross proceeds from sales.
- Regulatory Basis: Issued pursuant to an effective shelf registration statement on Form S-3 (File No. 333-230448).
Material Changes and Outlook
The primary material change is the authorization of an "at-the-market" offering, allowing the company to sell shares from time to time based on market conditions. The company retains the discretion to determine the amount and timing of sales and has no obligation to sell any shares. The offering may be suspended or terminated by either party upon notice. No specific financial guidance or outlook regarding future revenue or earnings was provided in this filing.
Risks and Contingencies
The agreement includes customary representations, warranties, and covenants. The company has agreed to indemnify Jefferies against certain liabilities, including those under the Securities Act of 1933. The sale of shares is subject to market conditions and applicable securities laws.
Investor Verification Checklist
- Verify the current share price and potential dilution impact of a $45 million offering.
- Review the full text of the Open Market Sale Agreement (Exhibit 1.1) for specific termination clauses and covenants.
- Confirm the company's current cash position and liquidity needs to understand the urgency of this financing.
- Check subsequent filings (e.g., 10-Q or 10-K) for actual proceeds generated under this agreement.